This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Cytomx Therapeutics, Inc.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Chanty Mariategue Chan: Innovator in Antibody Therapeutics
Introduction
Chanty Mariategue Chan is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of antibody therapeutics, particularly in the development of anti-PD1 antibodies. Her work focuses on innovative methods that enhance the efficacy of cancer treatments.
Latest Patents
Chanty holds a patent for "Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof." This invention relates to antibodies that specifically bind to programmed cell death protein 1 (PD-1). It also includes activatable antibodies that can be utilized in various therapeutic, diagnostic, and prophylactic applications. She has 1 patent to her name, showcasing her expertise in this critical area of research.
Career Highlights
Chanty is currently employed at CytomX Therapeutics, Inc., where she continues to advance her research in antibody development. Her work is pivotal in the ongoing efforts to improve cancer therapies and patient outcomes.
Collaborations
Chanty collaborates with notable colleagues, including Kimberly Ann Tipton and James William West. These partnerships enhance the innovative potential of her research and contribute to the success of their projects.
Conclusion
Chanty Mariategue Chan is a key figure in the field of antibody therapeutics, with a focus on anti-PD1 antibodies. Her contributions are vital to the advancement of cancer treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile